- Home
- SYBT vs ZLAB Comparison
SYBT vs ZLAB Comparison
Compare SYBT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- ZLAB
- Stock Information
- Founded
- SYBT 1904
- ZLAB 2013
- Country
- SYBT United States
- ZLAB China
- Employees
- SYBT N/A
- ZLAB N/A
- Industry
- SYBT Major Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- ZLAB Health Care
- Exchange
- SYBT Nasdaq
- ZLAB Nasdaq
- Market Cap
- SYBT 2.3B
- ZLAB 3.4B
- IPO Year
- SYBT N/A
- ZLAB 2017
- Fundamental
- Price
- SYBT $75.91
- ZLAB $31.92
- Analyst Decision
- SYBT Hold
- ZLAB Buy
- Analyst Count
- SYBT 3
- ZLAB 6
- Target Price
- SYBT $83.67
- ZLAB $57.22
- AVG Volume (30 Days)
- SYBT 86.3K
- ZLAB 807.7K
- Earning Date
- SYBT 10-22-2025
- ZLAB 11-11-2025
- Dividend Yield
- SYBT 1.63%
- ZLAB N/A
- EPS Growth
- SYBT 22.18
- ZLAB N/A
- EPS
- SYBT 4.35
- ZLAB N/A
- Revenue
- SYBT $364,546,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- SYBT $16.83
- ZLAB $42.62
- Revenue Next Year
- SYBT $5.12
- ZLAB $55.12
- P/E Ratio
- SYBT $17.44
- ZLAB N/A
- Revenue Growth
- SYBT 11.32
- ZLAB 32.56
- 52 Week Low
- SYBT $57.12
- ZLAB $20.17
- 52 Week High
- SYBT $83.83
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- SYBT 41.21
- ZLAB 46.25
- Support Level
- SYBT $76.66
- ZLAB $26.67
- Resistance Level
- SYBT $77.82
- ZLAB $33.06
- Average True Range (ATR)
- SYBT 1.77
- ZLAB 1.37
- MACD
- SYBT -0.53
- ZLAB 0.08
- Stochastic Oscillator
- SYBT 4.58
- ZLAB 66.14
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.